mikael dolsten md phd  pfizer one of the worlds premier biopharmaceutical companies sorry you need to enable javascript to visit this website careersworking heremission  purpose culture diversity  inclusion career growth  colleague development compensation  benefits ensuring corporate responsibility search jobs student  early careerpostdoctoral program us summer student worker program opportunities for veterans pfizercom our hiring  recruiting processfrequently asked questions tips for interviewing at pfizer connect with us investorsinvestors overviewwhy invest  our story prospective investors fact sheet events  presentations financialsquarterly reports annual reports sec filings interactive data filings investor news stock informationhistorical stock chart  data investment calculator historical price lookup dividend  split history stock faqs governanceboard committees and charters the pfizer board policies corporate governance faqs contact our directors shareholder servicesstock faqs cost basis calculator advisory information newspress release archive press statements company press kit vaccines press kit get old press kit pfizer oncology press kit ra narrative frequently requested info contact media relations partnerspartnership highlights contacts events pfizer is attending submit your opportunities biopharmaceuticals consumer healthcare core therapeutic areas innovation research  development venture investmentsour portfolio health professionals connect with usemail faq privacy policy youtube twitter facebook linkedin instagram en argentina australia austria belgium brazil canada china colombia czech republic denmark finland france germany greece hong kong hungary india indonesia ireland israel italy japan korea malaysiasingapore mexico netherlands new zealand norway pakistan philippines poland portugal romania russia slovakia south africa spain sweden switzerland taiwan thailand turkey united kingdom ukraine your health healthy living brain  nervous system cardiovascular health digestive health healthier aging living tobacco free men’s health mental health nutrition  fitness pediatric health respiratory health skin health vaccines  prevention women’s health disease  conditions cancer cardiovascular diseases  conditions diabetes  metabolic disorders immune system diseases  conditions infections  infectious diseases neurological diseases  conditions rare disease skin diseases  condition vaccinerelated conditions managing your health caregiving evaluating health information tracking your health your medicines hot topics hot topics the smoking epidemic a snapshot our science therapeutic areas metabolic disease  cardiovascular risk inflammation  immunology neuroscience  pain oncology rare disease vaccines product pipeline clinical trials what are clinical trials how clinical trials are conducted clinical innovation find a trial trial data  results post marketing commitments rd platforms biosimilars gene therapy medicinal sciences precision medicine collaboration collaboration ecosystem centers for therapeutic innovation competitive grants compound transfer program investigatorinitiated research rd collaborations research sites hot topics vaccines to fight sugarcoated bacteria this scientists life monique carter our people meet the experts scientists cardiovascular  metabolic disease immunology  inflammation neuroscience  pain oncology rare disease vaccines medical professionals the journey leadership executives board members company fact sheet diverse perspectives diversity  inclusion supplier diversity hot topics aspen ideas scholar austin huang aspen ideas scholar jackie conde our purpose responsibility individual voices building healthcare capacity expanding access to medicine corporate citizenship global institutions and partnerships reporting trends and progress protecting the environment pfizer’s green journey environment health  safety product stewardship positions on health policies ready for cures value of medicines how does pfizer price medicines policy positions transparency working with health care professionals sales and marketing compliance corporate compliance code of conduct patient assistance programs pfizer rx pathways goverment programs grants independent grants transparency in grants contributions  partnerships healthcare charitable contributions special charity events lobbying  political contributions hot topics read more our products product listing how drugs are made branded vs generic biologics  biosimilars commitment to quality distributors pfizer distributors greenstone distributors medicine and safety medicine safety medicine safety education reporting adverse events unused medicines sharps disposal counterfeiting safety data sheets medical information contacts hot topics the end of smallpox before it became a medicine you are hereour people  leadership  executive leadership  mikael dolsten md phd mikael dolsten md phd president worldwide research  development and executive vice president of pfizer inc mikael dolsten is focused on advancing the company’s scientific leadership in small molecule medicines biotherapeutics and vaccines he is a member of the pfizer executive leadership team and the company’s portfolio strategy and investment committee which governs major pipeline investments and strategic endtoend rd priorities he leads the worldwide research and development wrd organization at pfizer which is responsible for research at the company including development of all compounds through proof of concept and provides safety regulatory and clinical operation support to the entire rd pipeline the wrd group contains all pfizer research units including oncology cardiovascular  metabolic disease neuroscience inflammation  immunology vaccines rare disease as well as the centers for therapeutic innovation cti and the biotech unit rinat mikael also has worldwide responsibility for pfizer’s groups in safety regulatory and external rd innovation in addition to sciencebased teams in pharmaceutical sciences drug safety rd and large and small molecule discovery and development prior to joining pfizer in  mikael was president of wyeth research where he led scientists across the us europe and asia mikael earned his phd in tumor immunology and md from the university of lund in sweden where he was appointed adjunct professor in tumor immunology he is a fellow of the new york academy of medicine mikael serves on the science and regulatory executive committee of the pharmaceutical research and manufacturers of america phrma and the phrma foundation board of directors he is a member of the board of karyopharm pharmaceuticals and an industry member of the governmentuniversityindustry research roundtable guirr council in addition mikael was recently elected as foreign member of the royal swedish academy of engineering sciences mikael is a named inventor on several patents and has published approximately  articles in international journals with particular contributions in areas such as molecular cell biology immunology and oncology other people in executive leadership ian c read albert bourla dvm phd frank damelio chuck hill rady johnson doug lankler freda c lewishall md dfapa kirsten lundjurgensen phd rod mackenzie phd laurie j olson sally susman john young mikael dolsten pfizer inc president worldwide research  development  redbooks brands marketers agencies search less sell more    sign in get a free trial    contact us   mikael dolsten president worldwide research  development pfizer inc email realtime sales trigger feed  generated by redbooks machine learning and natural language processing technology tracking  news sources to aggregate all new executives jobrole changes and news on decision makers brands and agencies in the mediamarketing industry this sales feed is for mikael dolsten at pfizer inc mikael dolsten works as president worldwide research  development  acting in a executive management role  pfizer inc is a leader in pharmaceuticals  health care products  redbooks tracks personnel changes for advertisers spending over  million annually for more executive management leads or mediamarketing prospecting automation start a free trial now recent related news  in search of the keys to unlock immune systems “while the industry is looking to launch an array of precision medicines against cancer at the same time it is also working to unlock the intrinsic abilities of patients’ immune systems to fight off cancerous cells” pfizer’s president of worldwide research development mikael dolsten at the aspen ideas festival people in this article mikael dolsten  is sangamo therapeutics pointing toward success  pfizer made an initial payment of  million with up to  million in potential milestones with  million potential for additional gene therapies if opted by pfizer mikael dolsten president of worldwide research and development at pfizer stated we believe sb has the potential to be a bestinclass therapy that could provide stability to patients with a single administration treatment sgmo zfn technology had recently been overshadowed in market sentiment by nextgeneration genomeediting technologies such as crispr prior to the announcement  people in this article mikael dolsten learn more about mikael dolsten and  key contacts   create targeted lead lists   gain insider knowledge with advanced machine  learning   realtime verified contact info enter work email please enter email address please enter valid email address learn more about mikael dolsten and  key contacts first name  please enter first name last name  please enter last name company name  please enter company name email  phone  please enter phone number please enter  digits number what industry are you in    please select one the categories below please enter value for the industry  media sales  production  adtechmartech  sponsorship sales   agency new business   other what is your role    please select one the categories below please enter value for the role   csuite   vpmanager   sales rep   other thank you for registering for a free redbookscom trial we are processing your request and will be in touch shortly to get you started for immediate assistance please call us at   or email us at inforedbookscom home learn more free trial features ad think events thought leadership events top advertiser directory top agency directory add your agency update your agency agency showcase advertising associations creative spotlight services and suppliers about us blog contact us jobs terms  conditions privacy policy customer support   connect with us copyright   red books llc all rights reserved mikael dolsten  pfizer inc  email pfizercom login  day free trial mikael dolsten pfizer inc md export  east nd street new york ny  email format for pfizercom direct phone not available type public employees   revenue   billion industry biotechhealthcaremajor drugs sic code   pharmaceutical preparations biography mikael dolsten is the current md you can find mikael dolstens linkedin profile phone numbers wiki twitter and biography on pfizer incs lead profile as well as pfizer inc email addresses with the pfizercom domain format mikael dolstens email may or may not be inside the profile pfizer inc is situated in new york ny you can find their contact information on lead categorized under major drugs some possible email formats for mikael dolsten are mdolstenpfizercom mikaeldolstenpfizercom mikaelpfizercom and mikaeldolstenpfizercom if you sign up for our free trial you will see our emailpfizercom addresses similar people mikael d  other mikael d is the current senior front end developer you can find mikael ds linkedin profile phone numbers wiki twitter and biography on monigle associates incs lead profile as well as monigle associates inc email addresses with the moniglecom domain format mikael ds email may or may not be inside the profile monigle associates inc is situated in denver co you can find their contact information on lead categorized under software some possible email formats for mikael d are mdmoniglecom mikaeldmoniglecom mikaelmoniglecom and mikaeldmoniglecom if you sign up for our free trial you will see our emailmoniglecom addresses mikael dahan  other phil rogers is eidosmontrãals ceo their helpdesk technician is mikael dahan their lead profile is categorized under the computer hardware industry if youre checking for eidosmontrãal email addresses these are also available on lead with the eidosmontrealcom email format and possibly mikael dahans email eidosmontrãal is based in montreal qc you can also get mikael dahans linkedin info twitter phone numbers wiki and biography on their lead profile their contact information is filed under the computer hardware category some possible email formats for mikael dahan are mdahaneidosmontrealcom mikaeldahaneidosmontrealcom mikaeleidosmontrealcom and mikaeldahaneidosmontrealcom if you sign up for our free trial you will see our emaileidosmontrealcom addresses mikael dahl  executive kunio watanabe is nomuras ceo their managing director and group head is mikael dahl their lead profile is categorized under the investment bankbrokerage industry if youre checking for nomura email addresses these are also available on lead with the nomuracom email format and possibly mikael dahls email nomura is based in new york ny you can also get mikael dahls linkedin info twitter phone numbers wiki and biography on their lead profile their contact information is filed under the investment bankbrokerage category some possible email formats for mikael dahl are mdahlnomuracom mikaeldahlnomuracom mikaelnomuracom and mikaeldahlnomuracom if you sign up for our free trial you will see our emailnomuracom addresses similar employees anne hale  other anne hale is the current us business analytics and insights lead  specialty care you can find anne hales linkedin profile phone numbers wiki twitter and biography on pfizer incs lead profile as well as pfizer inc email addresses with the pfizercom domain format anne hales email may or may not be inside the profile pfizer inc is situated in new york ny you can find their contact information on lead categorized under major drugs some possible email formats for anne hale are ahalepfizercom annehalepfizercom annepfizercom and annehalepfizercom if you sign up for our free trial you will see our emailpfizercom addresses byron bond  executive ian read is pfizer incs ceo their senior director trade operations is byron bond their lead profile is categorized under the major drugs industry if youre checking for pfizer inc email addresses these are also available on lead with the pfizercom email format and possibly byron bonds email pfizer inc is based in new york ny you can also get byron bonds linkedin info twitter phone numbers wiki and biography on their lead profile their contact information is filed under the major drugs category some possible email formats for byron bond are bbondpfizercom byronbondpfizercom byronpfizercom and byronbondpfizercom if you sign up for our free trial you will see our emailpfizercom addresses linda werner  other linda werners email address phone numbers linkedin account wiki may be included in pfizer incs lead profile and other pfizer inc email addresses with the pfizercom domain format he is part of pfizer inc where he serves as the supply chain lead  associate research fellow pfizer incs main office is set in new york ny you can check their contact information on lead under the major drugs category some possible email formats for linda werner are lwernerpfizercom lindawernerpfizercom lindapfizercom and lindawernerpfizercom if you sign up for our free trial you will see our emailpfizercom addresses people directory  mikael dolsten mikael dolsten pfizer inc profile  biography  bloomberg feedback mikael dolsten presworldwide research  dev pfizer inc career history presworldwide research  dev pfizer inc present senior vppresworldwide pfizer inc  senior vpprespfizer biothera pfizer inc  senior vpwyethpresresearch wyeth  private equity partner orbimed advisors llc  global headcorporate boehringer ingelheim corp  show more website wwwpfizercom corporate information address  east nd street new york ny  united states phone 33 fax 38 web url wwwpfizercom from the web personal information education lund university md 88 lund university phd 88 memberships board memberships karyopharm therapeutics inc board member present sponsored financial commentaries more from the web home news top headlines most popular exclusive law entrepreneurs leaders economy environment science sports markets magazine pursuits magazine bloomberg visual data bloomberg best and worst for comments or complaints about news coverage click here regions us china europe asia uk  ireland australia  new zealand canada india  pakistan japan africa eastern europe latin america middle east markets commodities currencies bonds stocks energy markets municipal bonds emerging markets funds islamic finance industries energy technology real estate finance health care transportation insurance retail media manufacturing quick market data stocks stock futures world indexes americas europe middle east  africa asiapacific gainers  losers earnings calendar industry leaders currencies americas europe middle east  africa asiapacific foreign exchange cross rates fx fixings currency converter forex trading videos commodities energy prices metals prices agricultural prices rates  bonds us treasuries uk gilts germany bunds japan bonds australia bonds bloomberg bond indexes corporate bonds consumer rates economic calendar watchlist european debt crisis symbol search the market now personal finance top headlines saving  investing real estate retirement planning financial advisers taxes blog ventured  gained real cost of money gallery calculators watchlist portfolio tracker tech top headlines social media mobile  wireless web enterprise tech tv games  movies apple tech deals global tech slideshows videos us politics sustainability top headlines energy corporate sustainability policy natural resources health  population slideshows videos blog the grid luxury top headlines autos billionaires living property travel well spent loot blog pursuits magazine videos tv live tv channel finder personalities apple tv ipad app schedule us asia europe shows surveillance market makers lunch money street smart bloomberg west game changers video must see latest live tv shows playlist radio live radio shows schedule personalities podcasts bloomberg brief featured podcasts and new shows bloomberg view masters in business first word surveillance bloomberg advantage in the loop bloomberg law taking stock bloomberg best more podcasts blogs global tech the grid loot the market now political capital tech deals ventured and gained opinion my saved registration sign in bloombergcom businessweekcom company about blog careers diversity  inclusion news mission philanthropy  engagement press room procurement sustainability products financial products bloomberg professional service bloomberg anywhere bloomberg tradebook bloomberg briefs bloomberg indexes bloomberg sef service center customer support enterprise products enterprise solutions trading solutions industry products bloomberg bna bloomberg government bloomberg law bloomberg link bloomberg new energy finance bloomberg sports content licensing bloomberg anywhere mobile apps bloomberg visual data mikael dolsten md phd  karyopharm therapeutics careers contact mikael dolsten md phd board of directors mikael dolsten director dr dolsten has served as a member of our board of directors since march  he has served as the president of worldwide research and development and executive vice president of pfizer inc a biopharmaceutical company since december  dr dolsten served as president of worldwide research and development and senior vice president of pfizer inc from may  until december  and president of pfizer biotherapeutics research  development group and senior vice president of pfizer inc from october  until may  from june  to october  dr dolsten served as senior vice president of wyeth a biopharmaceutical company that was acquired by pfizer inc in october  and president wyeth research from june  to october  prior to joining wyeth dr dolsten was a private equity partner at orbimed advisors llc and executive vice president head of pharma research at boehringer ingelheim a pharmaceutical company dr dolsten also previously held research leadership positions at astrazeneca pharmacia and upjohn he is widely recognized as a leader within the medical research and drug development community meet garen bohlin director read next bio « previous bio overview mission management team board of directors scientific advisory board usakaryopharm therapeutics corporate headquarters 8 wells ave nd floor newton ma    main phone number usa 8 germanykaryopharm therapeutics sitz der gesellschaft karyopharm europe gmbh franziskabilekweg  833 münchen germany   tel   8 –  8 8 fax   8 –  8 8 general contact information about sine™ technology drug candidates investors publications contact careers   karyopharm therapeutics terms of use privacy policy pfizer appoints mikael dolsten president of worldwide research and development  pfizer pharmaceutical news and media  pfizer the worlds largest researchbased pharmaceutical company login health care professionals partnering careers contact us country finder argentina finland japan senegal asia pacific france korea slovakia australia germany malaysiasingapore south africa austria greece mexico spain belgium hong kong netherlands sweden brazil hungary new zealand switzerland canada india norway taiwan china indonesia pakistan thailand colombia ireland philippines turkey czech republic israel poland united kingdom denmark italy portugal venezuela home about pfizer leadership  structure corporate governance corporate compliance history accolades diversity research  development at pfizer product pipeline how rd works conducting research  clinical trials post marketing commitments investigatorinitiated research health  wellness medicine safety patient assistance programs vaccines senior health chief medical officer responsibility global health programs grants  contributions working with health care professionals protecting the environment workplace responsibility pfizer pharmaceutical products counterfeit  importation authorized distributors material safety data sheets animal health investors shareholder services financial reports sec filings ceocfo certifications presentations news  media press releases featured stories video gallery frequently requested info press kits social media contact pfizer media relations home news  media press releases pfizer appoints mikael dolsten president of worldwide research and development news  media press releasespress release archivepress statements archivefeatured storiesvideo galleryfrequently requested infopress kitsdownload multimediasocial mediacontact pfizer media relations pfizer appoints mikael dolsten president of worldwide research and development company concludes its integration of research functions wednesday may    am edt dateline new york emailpdfprintrss public company information nysepfe i am excited to have the opportunity to align the tremendous science that is in every corner of pfizer to bring forward medicines and vaccines that transform lives new yorkbusiness wiretoday pfizer inc named mikael dolsten md phd president of pfizer worldwide research and development as the company completes its integration of these functions following the wyeth acquisition dr dolsten previously led wyeth’s research and development organization from may  and after the close of the wyeth acquisition was named president of pfizer’s biotherapeutics research  development prior to his appointment at wyeth dr dolsten held key leadership roles in rd at boehringer ingelheim and astrazeneca with this appointment dr dolsten will now lead all of research at pfizer as well as development of all compounds through phase  or ‘proof of concept’ latestage clinical development will continue to be led by clinical teams throughout the worldwide biopharmaceutical businesses as announced in april  “since closing the wyeth acquisition we have rapidly advanced integration completing the pipeline portfolio review finalizing decisions regarding our rd network very quickly after close and steadily progressing the pipeline rapid integration has been enhanced by strong and steady collaboration between the two legacy rd groups  making the consolidation under one leader a natural and progressive step to take at this point” said jeffrey kindler pfizer’s chairman and chief executive officer the newly named pfizer worldwide research  development organization will maintain an rd structure that supports excellence in small molecules large molecules and vaccine research and development it will include biotherapeutics research and development focused on large molecules and biotechnologies pharmatherapeutics research and development focused on small molecules and vaccines research and development pfizer adopted a novel rd model following the wyeth acquisition to foster diversity of talent assets and culture as well as the empowerment and accountability of research leaders across rd pfizer initially implemented this model with a twodivision structure biotherapeutics and pharmatherapeutics to ensure the progress and steady integration of both legacy organizations due to the speed and effectiveness of the integration pfizer is now able to implement a diversified rd platform with the same breadth and research programs under the consolidated leadership of dr dolsten “mikael dolsten is an exceptional scientist who is highly regarded and committed to bringing new preventative measures treatments and cures to people mikael’s scientific expertise vision for rd and commercial mindset have distinguished him at pfizer and uniquely qualify him to lead our rd colleagues and advance our pipeline having all of pfizer’s research conducted under mikael’s leadership will enrich the alignment between our research programs and commercial teams to address important unmet medical needs and deliver the next generation of medicines” said mr kindler “i am excited to have the opportunity to align the tremendous science that is in every corner of pfizer to bring forward medicines and vaccines that transform lives” said dr dolsten “we have great skills in science we have industryleading technologies and i am very proud of our rd pipeline i look forward to working with our leaders to advance our effort to become the world’s premier biopharmaceutical rd group” pfizer also announced today the resignation of martin mackay president pharmatherapeutics research  development who will leave the company effective immediately dr dolsten will expand the role of rod mackenzie phd who is currently senior vice president and head of worldwide research for pharmatherapeutics rd in addition to his current responsibilities leading small molecule research dr mackenzie will add responsibility for asia rd strategy as well as small molecules pharmaceutical science “we thank martin mackay for his many accomplishments and greatly appreciate all he has done to help us develop worldclass scientists at pfizer” added mr kindler “i know mikael will work closely with rod and all of our leaders across pharmatherapeutics and biotherapeutics to ensure continuity of strategy and progress as we continue to build our science base at pfizer” said mr kindler “rod’s ability to transform pharmaceutical research has impressed me tremendously” said dr dolsten “i am excited he has accepted to take on an expanded new role and i look forward to a strong partnership to advance pfizer rd  and to serve people who rely on science and medicine for healthier and more productive lives” pfizer inc working together for a healthier world™ at pfizer we apply science and our global resources to improve health and wellbeing at every stage of life we strive to set the standard for quality safety and value in the discovery development and manufacturing of medicines for people and animals our diversified global health care portfolio includes human and animal biologic and small molecule medicines and vaccines as well as nutritional products and many of the world’s bestknown consumer products every day pfizer colleagues work across developed and emerging markets to advance wellness prevention treatments and cures that challenge the most feared diseases of our time consistent with our responsibility as the world’s leading biopharmaceutical company we also collaborate with health care providers governments and local communities to support and expand access to reliable affordable health care around the world for more than  years pfizer has worked to make a difference for all who rely on us to learn more about our commitments please visit us at wwwpfizercom contact pfizer incmediaray kerins 333investorscharles e triano  333 contact us investors sitemap careers business to business terms of use global network health care professionals privacy policy copyright  – pfizer inc all rights reserved this information is intended only for residents of the united states the product information provided in this site is intended only for residents of the united states the products discussed herein may have different product labeling in different countries pfizer inc is a pharmaceutical company committed to helping people improve their health by discovering and developing medicines business wire newshq℠